We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis--a proof of principle and exploratory trial: is dose tapering practical in good responders?
- Authors
Ibrahim, Fowzia; Lorente-Cánovas, Beatriz; Doré, Caroline J.; Bosworth, Ailsa; Ma, Margaret H.; Galloway, James B.; Cope, Andrew P.; Pande, Ira; Walker, David; Scott, David L.
- Abstract
Objectives. RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response. Methods. We enrolled RA patients receiving etanercept or adalimumab and a DMARD with DAS28 under 3.2 for over 3 months. Initially (months ≽ 6) patients were randomized to control (constant TNFi) or two experimental groups (tapering TNFi by 33 or 66%). Subsequently (months 6-12) control subjects were randomized to taper TNFi by 33 or 66%. Disease flares (DAS28 increasing 50.6 with at least one additional swollen joint) were the primary outcome. Results. Two hundred and forty-four patients were screened, 103 randomized and 97 treated. In months 0-6 there were 8/50 (16%) flares in controls, 3/26 (12%) with 33% tapering and 6/21 (29%) with 66% tapering. Multivariate Cox analysis showed time to flare was unchanged with 33% tapering but was reduced with 66% tapering compared with controls (adjusted hazard ratio 2.81, 95% CI: 0.99, 7.94; P = 0.051). Analysing all tapered patients after controls were re-randomized (months 6-12) showed differences between groups: there were 6/48 (13%) flares with 33% tapering and 14/39 (36%) with 66% tapering. Multivariate Cox analysis showed 66% tapering reduced time to flare (adjusted hazard ratio 3.47, 95% CI: 1.26, 9.58; P = 0.016). Conclusion. Tapering TNFi by 33% has no impact on disease flares and appears practical in patients in sustained remission and low disease activity states. Trail registration: EudraCT, https://www.clinicaltrialsregister.eu, 2010-020738-24; ISRCTN registry, https://www.isrctn.com, 28955701
- Subjects
ETANERCEPT; ADALIMUMAB; ANTIRHEUMATIC agents; CLINICAL trials; CONFIDENCE intervals; LONGITUDINAL method; MULTIVARIATE analysis; PROBABILITY theory; RHEUMATOID arthritis; STATISTICAL sampling; TUMOR necrosis factors; DISEASE relapse; RANDOMIZED controlled trials; TREATMENT effectiveness; DISEASE remission; PROPORTIONAL hazards models; DESCRIPTIVE statistics; ODDS ratio; CHEMICAL inhibitors; THERAPEUTICS
- Publication
Rheumatology, 2017, Vol 56, Issue 11, p2004
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/kex315